| pubmed-article:2881837 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C0001964 | lld:lifeskim |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C0053532 | lld:lifeskim |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C0758515 | lld:lifeskim |
| pubmed-article:2881837 | lifeskim:mentions | umls-concept:C1512523 | lld:lifeskim |
| pubmed-article:2881837 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2881837 | pubmed:dateCreated | 1987-5-1 | lld:pubmed |
| pubmed-article:2881837 | pubmed:abstractText | Blocking activities of alpha- and beta-adrenoceptors by (+/-)-1-[[2-(3,4-dimethoxyphenyl)-ethyl]amino]-3-(3-methylphenoxy)-2 -propanol hydrochloride (NC-1400) were tested on the isolated muscles, comparing with those of labetalol and atenolol. In blocking the beta 1-adrenoceptor, NC-1400 was slightly more potent than labetalol and atenolol. NC-1400 was about 1/10th as potent as labetalol and about ten times as potent as atenolol in blocking the beta 2-receptor. NC-1400 was beta 1-adrenoceptor selective. NC-1400 was about 1/30th as potent as labetalol in blocking the alpha 1-receptor. NC-1400 did not interact with the alpha 2-adrenoceptor in concentrations up to 10(-5) M. The present results indicate that NC-1400 is the selective beta 1-adrenoceptor blocker with some blocking activity of alpha 1-adrenoceptors. | lld:pubmed |
| pubmed-article:2881837 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2881837 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2881837 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2881837 | pubmed:issn | 0306-3623 | lld:pubmed |
| pubmed-article:2881837 | pubmed:author | pubmed-author:TakayanagiII | lld:pubmed |
| pubmed-article:2881837 | pubmed:author | pubmed-author:IwasakiSS | lld:pubmed |
| pubmed-article:2881837 | pubmed:author | pubmed-author:KizawaYY | lld:pubmed |
| pubmed-article:2881837 | pubmed:author | pubmed-author:NakagoshiAA | lld:pubmed |
| pubmed-article:2881837 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2881837 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:2881837 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2881837 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2881837 | pubmed:pagination | 87-9 | lld:pubmed |
| pubmed-article:2881837 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:meshHeading | pubmed-meshheading:2881837-... | lld:pubmed |
| pubmed-article:2881837 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:2881837 | pubmed:articleTitle | (+/-)-1-[[2-(3,4-Dimethoxphenyl)ethyl]amino]-3-(3-methylphenoxy)-2- propanol hydrochloride (bevantolol, NC-1400) as a beta 1-selective adrenoceptor blocker with alpha 1-adrenoceptor blocking activity. | lld:pubmed |
| pubmed-article:2881837 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2881837 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2881837 | pubmed:publicationType | In Vitro | lld:pubmed |
